Chromogenic Life Sciences (India) Profile
Key Indicators
- Authorised Capital ₹ 11.50 Cr
as on 11-12-2024
- Paid Up Capital ₹ 2.17 Cr
as on 11-12-2024
- Company Age 14 Year, 3 Days
- Last Filing with ROC 31 Dec 2023
- Satisfied Charges ₹ 1.00 Cr
as on 11-12-2024
- Revenue 15.55%
(FY 2023)
- Profit 1.50%
(FY 2023)
- Ebitda 47.03%
(FY 2023)
- Net Worth -99.54%
(FY 2023)
- Total Assets -34.56%
(FY 2023)
About Chromogenic Life Sciences (India)
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 December 2023. It's a company limited by shares with an authorized capital of Rs 11.50 Cr and a paid-up capital of Rs 2.17 Cr.
The company has closed loans amounting to ₹1.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Shivani Desai and Rabindra Chakraborty serve as directors at the Company.
- CIN/LLPIN
U24232TG2011PTC072156
- Company No.
072156
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jan 2011
- Date of AGM
21 Jun 2024
- Date of Balance Sheet
31 Dec 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Chromogenic Life Sciences (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivani Desai  | Whole-Time Director | 13-Jan-2020 | Current |
| Rabindra Chakraborty | Whole-Time Director | 24-May-2021 | Current |
Financial Performance of Chromogenic Life Sciences (India).
Chromogenic Life Sciences (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.55% increase. The company also saw a slight improvement in profitability, with a 1.5% increase in profit. The company's net worth observed a substantial decline by a decrease of 99.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chromogenic Life Sciences (India)?
In 2023, Chromogenic Life Sciences (India) had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Trilogy Analytical Laboratory Private LimitedActive 9 years 9 monthsShivani Desai and Rabindra Chakraborty are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 29 Mar 2011 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Chromogenic Life Sciences (India)?
Chromogenic Life Sciences (India) has a workforce of 15 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chromogenic Life Sciences (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chromogenic Life Sciences (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
